Treatment for Infectious Mononucleosis
Treatment of infectious mononucleosis is primarily supportive, with rest, hydration, and symptom management; routine use of antivirals and corticosteroids is not recommended for uncomplicated cases 1, 2.
Core Management Approach
Supportive Care (First-Line)
- Adequate hydration, analgesics, and antipyretics form the foundation of treatment 2
- Activity should be guided by the patient's energy level rather than enforced bed rest 2
- Reduction of activity and rest as tolerated are appropriate 3
Symptom Management
- Fever and pharyngitis respond to standard analgesics/antipyretics
- Fatigue may persist for 3 months but typically resolves spontaneously 3
- Myalgias and need for sleep may continue for several months after acute infection 2
When NOT to Use Routine Medications
Corticosteroids
Corticosteroids are NOT recommended for routine treatment 2. However, they may benefit specific severe presentations:
- Respiratory compromise
- Severe pharyngeal edema 2
The evidence is clear that routine corticosteroid use should be avoided in uncomplicated infectious mononucleosis.
Antivirals
Routine antiviral therapy (acyclovir, valacyclovir) is not recommended 2. Limited evidence suggests antivirals may have a role only in:
- Severe infectious mononucleosis with complications 4
- Immunosuppressed populations at higher risk of severe disease 1
Antihistamines
Not recommended for routine treatment 2.
Critical Activity Restrictions
Patients must avoid contact sports and strenuous exercise for at least 3-4 weeks from symptom onset 1, 2. The most recent guideline recommends:
- 3 weeks minimum restriction from athletic activity 1
- Some sources suggest 4 weeks or until splenomegaly resolves 2, 5
- Shared decision-making should guide return to activity timing 1
This restriction is essential because splenic rupture occurs in 0.1-0.5% of patients and is potentially life-threatening 3. Splenomegaly occurs in approximately 50% of cases 3.
Special Populations
Immunosuppressed Patients
These patients are at higher risk of severe disease and significant morbidity 1. Consider:
- More aggressive monitoring
- Potential role for antiviral therapy in complicated cases 4
Common Pitfalls to Avoid
- Do not prescribe antibiotics empirically - If given ampicillin or amoxicillin, 10-45% of patients develop a characteristic rash 3
- Do not allow premature return to sports - Risk of splenic rupture is the most feared complication
- Do not routinely use corticosteroids - Reserve only for airway compromise or severe pharyngeal edema
- Do not enforce strict bed rest - Activity as tolerated is appropriate
Expected Clinical Course
Most patients have an uneventful recovery 3. The disease is generally benign and self-limited 3. However, clinicians should monitor for: